Access brought to you by: LOCKSS

Diabetes & Endocrinology Clinical Trials

Insulin Dose Not Linked to Cardiovascular Mortality in the ACCORD Trial
Education Improves Hypoglycemia Awareness Regardless of Technology Used for Insulin Delivery
Cardiovascular Safety of Linagliptin in Patients with Type 2 Diabetes
Impact of LX4211 on Cardiovascular Risk Factors in Type 2 Diabetes
ORIGIN Trial: Insulin Glargine and n-3 Fatty Acids Neither Reduces CV Events Nor Increases Cancers in Diabetic Patients
Exenatide Once Weekly Sustained Improvement in Glycemic Control with Weight Loss through 4 Years
DiaPep277® Shows Promise as a Therapeutic Strategy for Type 1 Diabetes
Linagliptin Proves Safe and Effective as Add-on Therapy to Basal Insulin
12-Week Treatment with LY2409021 Significantly Lowers HbA1C and Is Well Tolerated in Patients with Type 2 Diabetes Mellitus
Insulin Degludec is Superior to Sitagliptin in Improving Glycemic Control in Uncontrolled Patients with Type 2 Diabetes on Oral Agents

Pages